Blackstone closed its largest life sciences private fund on record, raising $6.3 billion for the Blackstone Life Sciences platform (BXLS). The fund is nearly 40% larger than the firm’s prior $4.6 billion predecessor, reinforcing Blackstone’s role as a major capital source tied to innovation-stage and commercial-stage life sciences assets. Blackstone said partnerships under BXLS have produced 34 approved innovative medicines and devices, and it highlighted high approval rates in late-stage assets. The closing arrives amid ongoing life sciences deal flow tied to royalty and R&D funding structures. The scale of the fund matters for biotech because it signals sustained private capacity to finance late-stage development, platform commercialization, and royalty-backed investments that can complement clinical trial funding needs.